Amado J. Zurita

Jan 9, 2025 | nature.com | Pavlos Msaouel |Rahul Sheth |Amishi Y. Shah |Amado J. Zurita |Giannicola Genovese |Minghao Dang | +3 more

AbstractWe conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. The primary endpoint was safety.

Jul 16, 2024 | nature.com | Andrew Hahn |Rebecca S. Tidwell |Amado J. Zurita |Sumit K. Subudhi |Pavlos Msaouel |Efstratios Koutroumpakis | +2 more

AbstractAndrogen signaling is central to prostate cancer and men’s health. Prior data indicates that increasing body fat is unfavorable in the localized setting yet associated with favorable outcomes in men with metastatic disease. Understanding the biological links between adiposity and prostate cancer may optimize the therapeutic index with ASI.

May 10, 2023 | nature.com | Jose A. Karam |Pavlos Msaouel |Cara Haymaker |Surena F. Matin |Matthew Campbell |Amado J. Zurita | +4 more

AbstractSitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521).